clinical-trials

To interpret clinical trial effect sizes, standardize primary and secondary outcomes including HR, OR, RR, and ARR with clinical context. Evaluate precision using confidence intervals and translate findings into actionable metrics like NNT or NNH for clinical relevance.

Assess risk of bias and CONSORT reporting quality by applying CONSORT 2010 guidelines to evaluate trial generalizability. Identify common pitfalls such as surrogate endpoints, non-pre-specified subgroups, and sponsor bias to ensure accurate interpretation of randomized controlled trials.

Yes, you can interpret non-inferiority, adaptive, and observational studies using this approach. It applies standardized interpretation to various clinical trial designs, ensuring consistent evaluation of effect sizes, precision, and bias across different study methodologies.

Calculate MCID and NNT by translating absolute risk reduction and confidence intervals into clinically meaningful metrics. This involves assessing whether the effect size and precision meet the minimum clinically important difference threshold for patient-centered outcomes.

Common pitfalls when interpreting surrogate endpoints include overestimating clinical relevance, ignoring non-pre-specified subgroup analyses, and overlooking sponsor bias. Corrective phrasing templates help contextualize findings and mitigate these reporting and interpretational risks.